Transplantation in oncology: the future of a multidisciplinary approach

On February 7, 2019, a one-day Consensus Conference of the International Liver Transplantation Society was held to discuss oncology issues. Representatives of world's leading clinics gathered in Rotterdam (Netherlands). The presentations made on that day covered the following topics: hepatocellular cancer, bile duct cancer, immunotherapy and its place in the treatment of liver tumors, the possibility of liver transplantation in patients with metastatic liver disease, world trends in pediatric oncohepatology. A separate session in the working groups was allocated to discuss the most actual topics. The Conference identified the main global trends and the most crucial issues in the field of liver transplantation in patients with oncological diagnosis. It is likely that these presentations will “set the tone” for the large Transplantationt Congress in Toronto in May 2019.

1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. PMID: 27733281 https://doi.org/10.1016/S0140-6736(16)31012-1

2. Saez-Gonzalez E, Vinaixa C, San Juan F, Hontangas V, Benlloch S, Aguilera V, et al. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int. 2018;38(6):1022–1027. PMID: 29105320 https://doi.org/10.1111/liv.13618

3. Llovet JM. Liver cancer: time to evolve trial design after everolimus failure. Nat Rev Clin Oncol. 2014;11(9):506–507. PMID: 25091613 https://doi.org/10.1038/nrclinonc.2014.136

4. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–472. PMID: 26205340 https://doi.org/10.1038/nrc3973

5. Kudo M. Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2018;7(1):20–27. PMID: 29662830 https://doi.org/10.1159/000486487

6. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. PMID: 21374666 https://doi.org/10.1002/hep.24199

7. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–1977. PMID: 25689978 https://doi.org/10.1002/hep.27752

8. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, et al. Excellent Outcomes of Liver Transplantation Following down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018;16(6):955–964. PMID: 29175528 https://doi.org/10.1016/j.cgh.2017.11.037

9. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–994.e3; quiz e14–5. PMID: 22750200 https://doi.org/10.1053/j.gastro.2012.05.052

10. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64(6):2077–2088. PMID: 27178646 https://doi.org/10.1002/hep.28643

11. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–951. PMID: 24797281 https://doi.org/10.1002/lt.23904

12. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for HCC-a new MORAL to the story. Ann Surg. 2017;265(3):557-564. PMID: 27611615 https://doi.org/10.1097/SLA.0000000000001966

13. Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, Sugawara Y, et al. LTx- PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J Hepatobiliary Pancreat Sci. 2017;24(1):49–57. PMID: 27806426 https://doi.org/10.1002/jhbp.412

14. European Association for the Study of the Liver. Electronic address: easloffice@ easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. PMID: 29628281 https://doi.org/10.1016/j.jhep.2018.03.019

15. Llovet JM. Liver cancer: time to evolve trial design after everolimus failure. Nat Rev Clin Oncol. 2014;11(9):506–507. PMID: 25091613 https://doi.org/10.1038/nrclinonc.2014.136

16. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594–599. PMID: 27000463 https://doi.org/10.1634/theoncologist.2015-0446

17. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54(2):463–471. PMID: 21538440 https://doi.org/10.1002/hep.24397

18. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289. PMID: 24681130 https://doi.org/10.1016/j.jhep.2014.01.021

19. Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant. 2014;14(3):660–667. PMID: 24410861 https://doi.org/10.1111/ajt.12591

20. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–2338. PMID: 24769639 https://doi.org/10.1093/annonc/mdu162

21. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, et al. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014;5(6):408–413. PMID: 25436118 https://doi.org/10.3978/j.issn.2078-6891.2014.072

22. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016;34(3):219–226. PMID: 26503201 https://doi.org/10.1200/JCO.2015.61.3778

23. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847. PMID: 27622582 https://doi.org/10.1002/ cncr.30254

24. Dang L, White DW, Gross S, Bennett BD, Ghobrial RM, Bittinger A, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. PMID: 19935646 https://doi.org/10.1038/nature08617

25. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282. PMID: 29182496 https://doi.org/10.1200/JCO.2017.75.5009

26. Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163(4):732–738. PMID: 29336813 https://doi.org/10.1016/j.surg.2017.08.011

27. Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018;267(5):797–805. PMID: 29064885 https://doi.org/10.1097/SLA.0000000000002574

28. Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015;261(5):956–960. PMID: 24950280 https://doi.org/10.1097/SLA.0000000000000786

29. Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg. 2018;105(3):295–301. PMID: 29168565 https://doi.org/10.1002/bjs.10651

30. Grut H, Revheim ME, Line PD, Dueland S. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nucl Med Commun. 2018;39(7):621–627. PMID: 29683930 https://doi.org/10.1097/MNM.0000000000000843

31. Line PD, Hagness M, Berstad AE, Foss A, Dueland S. A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept. Ann Surg. 2015;262(1):e5–9. PMID: 25692361 https://doi.org/10.1097/SLA.0000000000001165

32. Czaudernaa P, Haeberleb B, Hiyamac E, Rangaswamid A, Ghobrial Krailoe RM, Maibachf R, et al. The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101. PMID: 26655560 https://doi.org/10.1016/j.ejca.2015.09.023

33. Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018;48(4):536–554. PMID: 29427028 https://doi.org/10.1007/s00247-018-4078-z

34. Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol. 2018;24(35):3980–3999. PMID: 30254403 https://doi.org/10.3748/wjg.v24.i35.3980